Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Prostate cancer risk prediction models in Eastern Asian populations: current status, racial difference, and future directions.

He BM, Chen R, Sun TQ, Yang Y, Zhang CL, Ren SC, Gao X, Sun YH.

Asian J Androl. 2019 Jun 11. doi: 10.4103/aja.aja_55_19. [Epub ahead of print]

2.

European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.

Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, Power R, O'Brien F, O'Malley KJ, Galvin DJ, Brendan Murphy T, William Watson R.

BJU Int. 2016 Nov;118(5):706-713. doi: 10.1111/bju.13437. Epub 2016 Feb 29.

3.

Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.

Trottier G, Roobol MJ, Lawrentschuk N, Boström PJ, Fernandes KA, Finelli A, Chadwick K, Evans A, van der Kwast TH, Toi A, Zlotta AR, Fleshner NE.

BJU Int. 2011 Oct;108(8 Pt 2):E237-44. doi: 10.1111/j.1464-410X.2011.10207.x. Epub 2011 Apr 20.

4.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

5.

Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.

Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15.

PMID:
22104592
6.

Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.

Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, Largo R, Wild P, Sulser T, Hermanns T.

BJU Int. 2016 Mar;117(3):401-8. doi: 10.1111/bju.13314. Epub 2015 Oct 5.

7.

Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index.

Roobol MJ, Vedder MM, Nieboer D, Houlgatte A, Vincendeau S, Lazzeri M, Guazzoni G, Stephan C, Semjonow A, Haese A, Graefen M, Steyerberg EW.

Eur Urol Focus. 2015 Sep;1(2):185-190. doi: 10.1016/j.euf.2015.06.004. Epub 2015 Jun 23.

PMID:
28723432
8.

Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?

Lee DH, Jung HB, Park JW, Kim KH, Kim J, Lee SH, Chung BH.

Yonsei Med J. 2013 May 1;54(3):665-71. doi: 10.3349/ymj.2013.54.3.665.

9.

Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy.

Chen R, Xie L, Xue W, Ye Z, Ma L, Gao X, Ren S, Wang F, Zhao L, Xu C, Sun Y; Chinese Prostate Cancer Consortium.

Urol Oncol. 2016 Sep;34(9):416.e1-7. doi: 10.1016/j.urolonc.2016.04.004. Epub 2016 May 12.

PMID:
27185342
10.

Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.

Louie KS, Seigneurin A, Cathcart P, Sasieni P.

Ann Oncol. 2015 May;26(5):848-64. doi: 10.1093/annonc/mdu525. Epub 2014 Nov 17. Review.

PMID:
25403590
11.

Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.

Gayet M, Mannaerts CK, Nieboer D, Beerlage HP, Wijkstra H, Mulders PFA, Roobol MJ.

Eur Urol Focus. 2018 Mar;4(2):228-234. doi: 10.1016/j.euf.2016.07.007. Epub 2016 Aug 4.

PMID:
28753781
12.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

13.

Prostate cancer risk assessment tools in an unscreened population.

Lundon DJ, Kelly BD, Foley R, Loeb S, Fitzpatrick JM, Watson RW, Rogers E, Durkan GC, Walsh K.

World J Urol. 2015 Jun;33(6):827-32. doi: 10.1007/s00345-014-1365-7. Epub 2014 Aug 5.

PMID:
25091862
14.

External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study.

De Nunzio C, Lombardo R, Tema G, Alkhatatbeh H, Gandaglia G, Briganti A, Tubaro A.

Urol Oncol. 2018 Aug;36(8):364.e1-364.e7. doi: 10.1016/j.urolonc.2018.05.010. Epub 2018 Jun 5.

PMID:
29880458
15.

[Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population].

Zhu XD, Zheng A, Wang ZQ, Shao Q.

Zhonghua Nan Ke Xue. 2018 Feb;24(2):142-146. Chinese.

PMID:
30156074
16.

Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men.

Jeong CW, Lee S, Jung JW, Lee BK, Jeong SJ, Hong SK, Byun SS, Lee SE.

PLoS One. 2014 Apr 7;9(4):e94441. doi: 10.1371/journal.pone.0094441. eCollection 2014.

17.

The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.

Wu YS, Zhang N, Liu SH, Xu JF, Tong SJ, Cai YH, Zhang LM, Bai PD, Hu MB, Jiang HW, Na R, Ding Q, Sun YH.

Asian J Androl. 2016 Nov-Dec;18(6):925-929. doi: 10.4103/1008-682X.181192.

18.

External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.

Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW.

Asian J Androl. 2012 Sep;14(5):738-44. doi: 10.1038/aja.2012.28. Epub 2012 May 7.

19.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169
20.

Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.

Pereira-Azevedo N, Verbeek JFM, Nieboer D, Bangma CH, Roobol MJ.

Transl Androl Urol. 2018 Feb;7(1):18-26. doi: 10.21037/tau.2017.12.21.

Supplemental Content

Support Center